RHO PHYTO BY AVICANNA, HEALTHCARE PRACTITIONER GUIDE

This guide provides healthcare practitioners with information to make informed decisions about how to incorporate medical cannabis into their practice. It covers administration, dosing and titration guidance, potential side effects, warnings and precautions, and how to recommend RHO Phyto products. The purpose of this document is to provide medical information and not to serve as providing medical advice. Healthcare practitioners are responsible to exercise professional judgment when recommending the use of medical cannabis to their patients based on individual needs and circumstances. Any recommendations contained within this guide do not replace the clinical judgement of healthcare practitioners.

  Read More >>>

MEDICAL CANNABIS 2.0 – ADVANCEMENTS IN CANNABINOID RESEARCH, PRODUCT OFFERINGS AND PATIENT ACCESS
The symposium presents the evolution of medical cannabis including the Avicanna-led advancements in R&D for novel cannabinoid delivery forms and formulations in addition to enhanced access for patients by Medical Cannabis by Shoppers. This year’s annual symposium coincides with the expected launch of Avicanna’s RHO Phyto advanced medical cannabis products and in the wake of COVID-19, a virtual format allows for a broader reach to global patients and the medical community.

Watch >>>

THE EMERGENCE OF BIOPHARMACEUTICAL CANNABINOIDS FROM RESEARCH & DEVELOPMENT TO CLINICAL TRANSLATION
The 2nd annual Avicanna Symposium, “The Emergence of Biopharmaceutical Cannabinoids – From Research & Development to Clinical Translation”, was held at the MaRS Discovery District (Canada’s premium launchpad for start-ups), Toronto, Canada on 25th March 2019. The Symposium was the first to be held in Canada by Avicanna, with the inaugural Symposium taking place in Santa Marta, Colombia, May 2018.

  Read More >>>

This is the first edition of our newsletter series, which will provide a range of bio-pharmaceutical topics and updates in the emerging field of cannabinoid research and clinical development. The objective of this newsletter is to create awareness of the latest and most significant cannabinoid-based research that is conducted worldwide, and available to the research community. Furthermore, we hope this newsletter serves to engage the medical and scientific community to continue building and fostering strong academic and clinical relationships.

  Read More >>>

In this edition of our newsletter series, we focus on a recent publication that reviews the medical evidence for the treatment of chronic non-cancer pain (CNCP) with medical cannabis. This publication emphasizes the importance of interpreting the evidence of cannabis-based treatments towards specific CNCP, which aligns with Avicanna’s scientific and evidence-based approach for developing its cannabinoid-based products.

  Read More >>>

This newsletter explores cannabinoid applications in the treatment of epilepsy. Currently, there is significant evidence supporting medical cannabis as an adjunctive solution in epilepsy aside other treatments, however, there remains a paucity for research that proves cannabinoid-based therapies to be both independent and sustainable solutions to this disorder.

  Read More >>>